Transluminal Technologies, LLC news

Asuncion, Paraguay, April 20, 2017 – Transluminal Technologies, LLC, a Syracuse, NY-based medical device company has announced today that they have successfully completed the First-in-Man clinical study of the velox LB large bore vascular closure device with 100% procedural success (10/10).

Methods:  Patients with a baseline common femoral artery (CFA) diameter of ≥ 6.0 mm were anti-coagulated with IV heparin and treated with ≥14 FR arterial sheaths.

Transluminal Technologies LLC. out of Syracuse, New York won the CE Mark for its velox CD Vascular Closure Device used to close arteriotomies following percutaneous femoral procedures. Closing arteries can be a challenge, eating up surgeons’ time just when it’s optimal to move the patient out of the OR. The velox CD device speeds up this process by delivering an implant that plugs the vessel wall from within.

The implant consists

Transluminal Technologies exhibits velox CD at the Transcatheter Cardiovascular Therapeutics conference in San Francisco, CA.

Transluminal Technologies has been assessed and approved by BSI Group America against the provisions of ISO 13485:2003. Successful registration assures the firm’s quality management systems comply with requirements established by the International Organization for Standardization (ISO). ISO 13485:2003 is an internationally recognized quality standard specifically focused on the medical device industry. Achieving this registration reflects the company’s demonstration of a quality m

In conjunction with Dr. Adrian Ebner MD, Transluminal Technologies presents the first successful use of the velox CD™ vascular closure device in a cohort of 14 patients. The innovative use of a biodegradable magnesium alloy to create a temporary mechanical closure promises to deliver an exciting step forward in rapid time-to-hemostasis, time-to-ambulation, and ease of re-access.